Framework Selection Can Influence Pharmacokinetics of a Humanized Therapeutic Antibody Through Differences in Molecule Charge

mAbs - United States
doi 10.4161/mabs.29809
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

CD26 Is a Potential Therapeutic Target by Humanized Monoclonal Antibody for the Treatment of Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2018English

A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients With Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake

Clinical Cancer Research
Cancer ResearchOncology
2005English

Human Antibody Bispecifics Through Phage Display Selection

English

Influence of Human OATP1B1, OATP1B3, and OATP1A2 on the Pharmacokinetics of Methotrexate and Paclitaxel in Humanized Transgenic Mice

Clinical Cancer Research
Cancer ResearchOncology
2012English

Natural Selection Through Maternal Influence

Heredity
Genetics
1964English

Synthesis of an Organoinsulin Molecule That Can Be Activated by Antibody Catalysis

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2001English

Structural Characterization of a Potent Humanized Anti-Cd38 Antibody in Phase I

Acta Crystallographica Section A: Foundations and Advances
Materials ScienceCondensed Matter PhysicsTheoretical ChemistryBiochemistryStructural BiologyInorganic ChemistryPhysical
2014English

Can Small Molecule Inhibitors of Glutaminyl Cyclase Be Used as a Therapeutic for Alzheimer's Disease?

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy